

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kristof Van Emelen et al.

Serial No.: 09/980,452

Art Unit: 1626

Filed

: November 30, 2001

Examiner: Fiona Powers

For

: AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR

BENZOPYRAN) DERIVATIVES

I hereby certify that this correspondence is being sent express mail with the United States Postal Service in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

(Date of Deposit)

Ellen Ciambrone Coletti
(Name of applicant/assignes/or Registered Representative)

W (U

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

[In accordance with \$1.129(a), this Information

☐ In accord	dance with	\$1.129(a), t	his Info	rmation	
Disclosure Statemer	nt is being	filed in co	nnection	with [] the
first or \square second A	fter Final	Submission,	therefo	re:	
☐ Sta	tement in A	Accordance wi	th §1.97	7(e)	
(at	tached); o:	r			
☐ Ple	ase charge	Deposit Acco	ount No.	10-	
075	0/ /	the fee of	\$180.00	as set	forth
in	§1.17(p).				

In accordance with \$1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in \$1.97(b) above but before the mailing date of either a Final
Action under \$1.113 or a Notice of Allowance under \$1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

	Statement in Accordance with \$1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).
☐ In	accordance with \$1.97(d), this Information
Disclosure St	atement is being filed after the mailing date of
either a Fina	l Action under §1.113 or a Notice of Allowance
under §1.311	but before the payment of the Issue Fee.
Applicant(s)	hereby petition(s) for consideration of this
Information D	isclosure Statement. Included are: Statement in
Accordance wi	th §1.97(e) as set forth below and the fee of
\$180.00 as se	t forth in §1.17(p).
_	
_ _	ies of each of the references listed on the
attached Form	PTO-1449 are enclosed herewith.
П Сор	ies of references listed on the attached Form PTC
	osed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
☐ Cor	pies of only foreign patent documents and non-
patent litera	ture are enclosed in accordance with 37 CFR 1.98
(a)(2). (The	U.S. patents and each U.S. patent application
publication 1	isted on the attached Form PTO-1449 are not

•

•

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows: EP 0106749 English equivalent US4,849,335 is enclosed, EP0004358 English equivalent GB2019837 is enclosed. Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1487/ECC. This form is submitted in triplicate. Respectfully submitted, Ellen Ciambrone Coletti Reg. No. 34,140 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2359 DATED: 7-22-10!

Under the Paperwork
Substitute for form 1449APTO

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

a collection of information unless it displays a	a valu OMB cultur humber.
Application Number	09/980,452
Filing Date	November 30, 2001
First Named Inventor	Emelen
Group Art Unit	1626
Examiner Name	Fiona Powers
Attorney Docket Number	JAB-1487

Examiner Initials	Cite	U.S. Patent Document			Date of Publication	Pages, Columns, Lines,
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
		3,910,930		Janssen et al.	10/07/1975	
		3,929,801		Janssen et al.	12/30/1975	
		4,849,335		Institut Pasteur	07/18/1989	
		5,137,901		Junge et al.	08/11/1992	
		5,371,094		Heine et al.	12/06/1994	
		5,492,918		Wild et al.	02/20/1996	
		5,541,199		Mewshaw	07/30/1996	
		6,133,277		Wigerinck et al.	10/17/2000	,
		US2004/0019051	A1	Van emelen et al.	01/29/2004	
	 			·		
	Ţ					

		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴ Ki	ndCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T [®]
		PCT	WO 00/75137	A1	Janssen Pharmaceutica N.V.	12/14/2000		
		РСТ	WO 01/98306	A1	Janssen Pharmaceutica N.V.	12/27/2001		
		PCT	WO 95/05383	A1	Janssen Pharmaceutica N.V.	02/23/1995		
		EPO	0004358	B1	Ciba-Geigy AG	01/06/1982		
		EPO	0106749	B1	Institut Pasteur	12/21/1988		
		GB	2019837	Α	Ciba-Geigy AG	11/07/1979		ــــــ
								<u> </u>

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

JUL 2 2 2004

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

tute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		T. ARAKAWA, U. HIRONORI, F. TAKASHI, K. HIGUCHI, K, KOBAYASHI, T. KUROKI, New Aspects of Gastric Adaptive Relaxation, Reflex after Food Intake for More Food: Involvement of Capsaicin-sensitive Sensory Nerves and Nitric Oxide, 1997, J. Smooth Muscle Res. 33:81-88	

Examiner	Da	ate	
Signature	Co	onsidered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.